In patients with chronic myeloid leukemia (CML), ceasing tyrosine kinase inhibitor (TKI) therapy is safe and associated with much better patient-reported results, a nonrandomized trial exposes. Reuters Health Details
Read More
In patients with chronic myeloid leukemia (CML), ceasing tyrosine kinase inhibitor (TKI) therapy is safe and associated with much better patient-reported results, a nonrandomized trial exposes. Reuters Health Details
Read More